Citeline Introduces Global Patient Insights
May 15, 2024 09:00 ET
|
Citeline
Citeline announces the launch of Global Patient Insights, the industry’s most comprehensive view of the worldwide patient landscape.
Third Harmonic Bio Announces First Quarter 2024 Financial Results and Provides Business Update
May 15, 2024 08:05 ET
|
Third Harmonic Bio
U.S. FDA clears Investigational New Drug application for THB335 Phase 1 SAD/MAD clinical trial initiated and subject screening underway, with results expected during 1H’25 Strengthened leadership...
Global PIM Kinase Targeted Therapies Market Opportunity & Clinical Trials Report 2024: USA Dominating with 5 Therapies, FDA Orphan Designation, Proprietary Development Technologies by Companies
May 14, 2024 05:38 ET
|
Research and Markets
Dublin, May 14, 2024 (GLOBE NEWSWIRE) -- The "Global PIM Kinase Targeted Therapies Market Opportunity & Clinical Trials Insight 2024" report has been added to ResearchAndMarkets.com's offering....
Science 37 Metasite™ Undergoes Successful FDA Inspection, Marking Major Milestone in Virtual Site Quality Assurance and Compliance
May 13, 2024 08:00 ET
|
Science 37, Inc.
Science 37 Holdings, Inc. today announced the preliminary outcome of its recent FDA Inspection focusing on critical areas and documentation.
TrialWire Patient Recruitment Platform that Reboots Stalled Clinical Trials announced as Multi-Award Finalist in the 2024 Citeline Awards
May 12, 2024 16:29 ET
|
TrialWire
The TrialWire™ Rapid Patient Recruitment Platform, the only pay-per-enrolled fixed-fee solution powered by AI and algorithms, has been select for 3 awards
Tevogen Bio Announces Up to $50 Million in Financing to Further Advance Operational Objectives
May 10, 2024 17:40 ET
|
Tevogen Bio Inc
$50 million in financing advances operational objectives and bolsters a financial path to positive cashflow with minimal dilution.
Science 37 Wins 2024 MedTech Breakthrough Award for “Clinical Efficiency Innovation”
May 09, 2024 10:00 ET
|
Science 37, Inc.
Science 37 announces its selection as the winner of the “Clinical Efficiency Innovation Award” in the 8th annual MedTech Breakthrough Awards program.
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review
May 08, 2024 07:25 ET
|
ALTERITY THERAPEUTICS LIMITED
- ATH434-201 Trial on Track to Complete in November 2024 – - Top-Line Data Expected in January 2025 - MELBOURNE, Australia and SAN FRANCISCO, May 08, 2024 (GLOBE NEWSWIRE) --...
Fragile X Syndrome Global Clinical Trials Review 2024: Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End Point Status
May 03, 2024 06:25 ET
|
Research and Markets
Dublin, May 03, 2024 (GLOBE NEWSWIRE) -- The "Fragile X Syndrome - Global Clinical Trials Review, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.The analyst's clinical...
Global Graft Versus Host Disease (GVHD) Clinical Trials Review 2024
May 03, 2024 06:01 ET
|
Research and Markets
Dublin, May 03, 2024 (GLOBE NEWSWIRE) -- The "Graft Versus Host Disease (GVHD) - Global Clinical Trials Review, 2024" report has been added to ResearchAndMarkets.com's offering.This report will...